Evidence map›Paper›PMID 32528889›Full record

ArticleFrontiers in oncology2020

Checkpoint Inhibition for Metastatic Urothelial Carcinoma After Chemotherapy-Real-World Clinical Impressions and Comparative Review of the Literature.

Christian Fuhrmann, Julian P Struck, Philipp Ivanyi, Mario W Kramer, Marie C Hupe, Bennet Hensen, Alexander Fürschke, Inga Peters, Axel S Merseburger, Markus A Kuczyk and 1 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
2.2field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 13 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Review
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Christian FuhrmannClinic for Urology and Urological Oncology, Hanover Medical School, Hanover, Germany.
Julian P StruckDepartment of Urology, University Hospital Schleswig-Holstein, Luebeck, Luebeck, Germany.
Philipp IvanyiDepartment of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hanover Medical School, Hanover, Germany.
Mario W KramerDepartment of Urology, University Hospital Schleswig-Holstein, Luebeck, Luebeck, Germany.
Marie C HupeDepartment of Urology, University Hospital Schleswig-Holstein, Luebeck, Luebeck, Germany.
Bennet HensenInstitute of Diagnostic and Interventional Radiology, Hanover Medical School, Hanover, Germany.
Alexander FürschkeClinic for Radiology and Nuclear Medicine, University Hospital Schleswig-Holstein, Luebeck, Luebeck, Germany.
Inga PetersClinic for Urology and Urological Oncology, Hanover Medical School, Hanover, Germany.
Axel S MerseburgerDepartment of Urology, University Hospital Schleswig-Holstein, Luebeck, Luebeck, Germany.
Markus A KuczykClinic for Urology and Urological Oncology, Hanover Medical School, Hanover, Germany.
Christoph-A J von KlotClinic for Urology and Urological Oncology, Hanover Medical School, Hanover, Germany.
Medizinische Hochschule Hannover · DEUniversity of Lübeck · DEUniversity Hospital Schleswig-Holstein · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

atezolizumabcheckpoint inhibitionimmunotherapymetastatic urothelial carcinomanivolumabpembrolizumab

Identifiers

PMID32528889
PMCPMC7253725
OpenAlexW3028058636

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.